|
|
|
|
Clinical Comparison of 12 mg Ropivacaine and 8 mg Bupivacaine, Both with 20 microg Fentanyl, in Spinal Anaesthesia for Major Orthopaedic Surgery in Geriatric Patients
Erturk E et al.The data showed that 12 mg of ropivacaine and 8 mg of bupivacaine with 20 microg fentanyl in spinal anaesthesia can provide sufficient motor and sensory block for major orthopaedic surgery in geriatric patients. Clinical Comparison of...
|
|
|
Surgical tech in Rose hepatitis C case will leave fate to judge
Kristen Parker, the former surgical technician at Denvers Rose Medical Center linked to a wave of hepatitis C infections among patients, told a U.S.District Court judge Friday that she wants to move forward with a plea agreement she reached earlier while...
|
|
|
Research from University of Virginia in the area of granuloma published
- (NewsRx.com) 'As> 95,000 spinal drug-delivery devices have been implanted since their inception in the 1980s, the recognition of associated adverse effects is essential (see also Granuloma).Since 1985, numerous reports have described the presence of...
|
|
|
Gastroenterology: Recent findings from Naval Medical Center, Department of Anesthesiology highlight research in gastroenterology
Today's Medical & Research News Gastroenterology Recent findings from Naval Medical Center, Department of Anesthesiology highlight research in gastroenterology February 8th, 2010 Printer-Friendly Version City:San Diego State:CA Country:United States Abscess...
|
|
|
Fentanyl Buccal Bests Immediate-Release Oxycodone for Breakthrough Pain Relief: Presented at AAPM
-- Among patients with chronic pain, onset of analgaesia for breakthrough pain (BTP) is faster with oral fentanyl buccal, compared with immediate-release oxycodone, according to a study presented here at the 26th annual meeting of the American Academy of...
|
|
|
Fentanyl Buccal Bests Immediate-Release Oxycodone for Breakthrough Pain Relief: Presented at AAPM
-- Among patients with chronic pain, onset of analgaesia for breakthrough pain (BTP) is faster with oral fentanyl buccal, compared with immediate-release oxycodone, according to a study presented here at the 26th annual meeting of the American Academy of...
|
|
|
AKELA Pharma Inc. - Financial And Strategic Analysis Review - New Report Published
Newly released report, AKELA Pharma Inc.- Financial and Strategic Analysis Review, provides detailed company analysis (Companiesandmarkets.com and OfficialWire) LONDON, ENGLAND AKELA Pharma Inc. - Financial and Strategic Analysis Review Summary The "AKELA...
|
|
|
Obstetrics: Stanford University, Department of Anesthesia publishes research in obstetrics
Today's Medical & Research News Obstetrics Stanford University, Department of Anesthesia publishes research in obstetrics February 6th, 2010 Printer-Friendly Version City:Stanford State:California Country:United States Analgesia Analgesic Anesthesia...
|
|
|
Prostrakan, the Borders-based speciality pharmaceutical group, yesterday said its cancer-pain relief drug Abst
The Galashiels-based company said that the regulatory new drug submission had been made by its Canadian partner, Paladin Labs.Abstral, which is already marketed in Europe and was accepted for review by the US Food and Drug Administration in October, is a...
|
|
|
TopAbstracts in Pain 02/04/2010
TopAbstracts in Pain are the abstracts most highly rated/most read by nearly 300,000 physicians who received a Doctor's Guide newsletter or visited a website Powered by Doctor's Guide in the past 7 days.Over 2000 peer-reviewed journals are covered by...
|
|
|
Akela announces results of legal cases
AUSTIN, TX, Feb.4 /CNW Telbec/ - Akela (TSX: AKL) a leader in the development of therapeutics for the treatment of pain and its wholly owned subsidiary, PharmaForm, a leader in the contract pharmaceutical development and manufacturing business, today...
|
|
|
Akela announces results of legal cases
AUSTIN, TX, Feb.4 /CNW Telbec/ - Akela (TSX: AKL) a leader in the development of therapeutics for the treatment of pain and its wholly owned subsidiary, PharmaForm, a leader in the contract pharmaceutical development and manufacturing business, today...
|
|
|
Paladin Granted Priority Review Status for Abstral by Health Canada
MONTREAL, QUEBEC--(Marketwire - Feb.4, 2010) - Paladin Labs Inc. (TSX:PLB), a leading Canadian specialty pharmaceutical company, announced today that it has filed a new drug submission for Abstral sublingual fentanyl. The submission has been...
|
|
|
Paladin Granted Priority Review Status for Abstral(R) by Health Canada
Paladin Labs Inc.(TSX: PLB), a leading Canadian specialty pharmaceutical company, announced today that it has filed a new drug submission for Abstral(R) sublingual fentanyl. The submission has been accepted for priority review by Health Canada which...
|
|
|
Paladin Granted Priority Review Status for Abstral by Health Canada
MONTREAL, QUEBEC--(Marketwire - Feb.4, 2010) - Paladin Labs Inc. (TSX:PLB), a leading Canadian specialty pharmaceutical company, announced today that it has filed a new drug submission for Abstral(R) sublingual fentanyl. The submission has been...
|
|
|
Orexo confirms Canadian Regulatory Filing of Abstral
Orexo AB (STO: ORX) today confirms that its partner, ProStrakan Group plc (LSE: PSK) has announced that the New Drug Submission made by their Canadian partner, Paladin Labs Inc., for AbstralTM has been accepted for review by Health Canada, the Canadian...
|
|
|
Orexo confirms Canadian Regulatory Filing of Abstral
- Orexo AB (STO: ORX) today confirms that its partner, ProStrakan Group plc (LSE: PSK) has announced that the New Drug Submission made by their Canadian partner, Paladin Labs Inc., for AbstralTM has been accepted for review by Health Canada, the Canadian...
|
|
|
ProStrakan cancer drug up for review in Canada
Prostrakans cancer-pain relief drug Abstral had been accepted for review by Health Canada heraldscotland staff Prostrakan, the Borders-based speciality pharmaceutical group, yesterday said its cancer-pain relief drug Abstral had been accepted for review by...
|
|
|
Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Results and Conduct Conference Call on Wednesday, February 17, 2010
(MARKETWIRE via COMTEX) ----Auxilium Pharmaceuticals, Inc.(NASDAQ: AUXL), a specialty biopharmaceutical company, will release results for the fourth quarter and full year 2009 on Wednesday, February 17, 2010 before the opening of the financial markets. The...
|
|
|
Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Results and Conduct Conference Call on Wednesday, February 17, 2010
Companies mentioned in this article: Auxilium Pharmaceuticals, Inc.MALVERN, PA -- (Marketwire) -- 02/04/10 -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, will release results for the fourth quarter and full year...
|
|
|
Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Results and Conduct Conference Call on
MALVERN, PA--(Marketwire - 02/04/10) - Auxilium Pharmaceuticals, Inc.(NASDAQ:AUXL - News), a specialty biopharmaceutical company, will release results for the fourth quarter and full year 2009 on Wednesday, February 17, 2010 before the opening of the...
|
|
|
Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Results and Conduct Conference Call on Wednesday, February ..
MALVERN, PA -- (Marketwire) -- 02/04/10 -- Auxilium Pharmaceuticals, Inc.(NASDAQ: AUXL), a specialty biopharmaceutical company, will release results for the fourth quarter and full year 2009 on Wednesday, February 17, 2010 before the opening of the financial...
|
|
|
Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Results and Conduct Conference Call on Wednesday, February 17, 2010
MALVERN, PA -- (MARKET WIRE) -- 02/04/10 -- Auxilium Pharmaceuticals, Inc.(NASDAQ: AUXL), a specialty biopharmaceutical company, will release results for the fourth quarter and full year 2009 on Wednesday, February 17, 2010 before the opening of the...
|
|
|
Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Results and Conduct Conference Call on Wednesday, February 17, 2010
MALVERN, PA -- (MARKET WIRE) -- 02/04/10 -- Auxilium Pharmaceuticals, Inc.(NASDAQ: AUXL), a specialty biopharmaceutical company, will release results for the fourth quarter and full year 2009 on Wednesday, February 17, 2010 before the opening of the...
|
|
|
Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Results and Conduct Conference Call
MALVERN, PA -- (Marketwire) -- 02/04/10 -- Auxilium Pharmaceuticals, Inc.(NASDAQ: AUXL), a specialty biopharmaceutical company, will release results for the fourth quarter and full year 2009 on Wednesday, February 17, 2010 before the opening of the financial...
|
